Results 61 to 70 of about 214,611 (264)

HER2-low and ultralow breast cancer: interobserver challenges and lessons from a consensus study [PDF]

Journal of Pathology and Translational Medicine
Background The recent approval of trastuzumab deruxtecan for human epidermal growth factor receptor 2 (HER2)–low and HER2-ultralow breast cancer mandates an adequate assessment of these categories.
Jiwon Koh, Yoon Jin Cha, Eun Yoon Cho, Ahwon Lee, Ja Seung Koo, So Yeon Park, Min Hwan Kim, Jae Ho Jeong, Gyungyub Gong   +8 more
doaj   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Structural biology of HER2/ERBB2 dimerization: mechanistic insights and differential roles in healthy versus cancerous cells

Exploration of Medicine
Aim: Present study was done to understand the dimerization of HER2/ERBB2 in normal and cancer cells using in-silico study. Methods: Pathway analysis was done using Reactome.
Jayasree Santhanakrishnan, Prabhu Meganathan, Hemamalini Vedagiri   +2 more
doaj   +1 more source

EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides

Radiology and Oncology, 2015
Background. There is limited effect of tyrosine kinase inhibitors or “naked” antibodies binding EGFR or HER2 for therapy of metastasized urinary bladder cancer and these methods are therefore not routinely used.
Carlsson Jörgen, Wester Kenneth, De La Torre Manuel, Malmström Per-Uno, Gårdmark Truls   +4 more
doaj   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

The development of potential targets in the treatment of non-small cell lung cancer

Open Life Sciences, 2016
The oncogenic driver mutations have been found that not only have potential sensitivity to epidermal growth factor receptor but also can inhibit anaplastic lymphoma kinase tyrosine kinase; more and more interest has been evoked in discovering additional ...
Zhang Jimin, Lin Zhihui
doaj   +1 more source

Survival Outcomes in Older Adults with Axial Spondyloarthritis and Concomitant Cancer

Arthritis Care &Research, Accepted Article.
Objective The objective of this study was to determine survival outcomes in older adults with axial spondyloarthritis (axSpA) and concomitant cancer. Methods We conducted a population‐based study using Medicare claims data linked to Surveillance, Epidemiology, and End Results data to determine overall survival (OS) and cancer‐specific survival (CSS) in
Savannah Bowman, Mei Li, Xiudong Lei, Hui Zhao, Juan I. Ruiz, Sharon H. Giordano, Alexis R. Ogdie, Maria E. Suarez‐Almazor   +7 more
wiley   +1 more source

A targeted immunotherapy approach for HER2/neu transformed tumors by coupling an engineered effector domain with interferon-γ

OncoImmunology, 2018
Despite substantial clinical progress with targeted therapies, current antibody-based approaches have limited efficacy at controlling HER2/neu-positive breast cancers, especially in the absence of chemotherapies.
Hongtao Zhang, Lian Lam, Yasuhiro Nagai, Zhiqiang Zhu, Xi Chen, Mei Q. Ji, Mark I. Greene   +6 more
doaj   +1 more source

Microfluidic Nano‐Assembly of Red‐Blood‐Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles

Advanced Healthcare Materials, EarlyView.
Engineered red blood cell‐derived extracellular vesicles (eRBCEVs) are synthesized via controlled microfluidic assembly from native RBC lipids, enabling tunable encapsulation of proteins, nucleic acids, nanoparticles, and viral vectors. The platform demonstrates reproducible nanoscale architecture, preserved membrane composition, and functional cargo ...
Chiranth K. Nagaraj, Xilal Y. Rima, Kim T. Nguyen, Courtney Culkins, Nana Boateng, Jacob Doon‐Ralls, Alejandro Bresolin, Xin Huang, Hong Li, Vahedi Amid, Ajeet Pal Singh, Dharti Shantaram, Anastasiia Amari, Mangesh D. Hade, Nicholas R. Merriam, Zachary D. Schultz, Scott Q. Harper, Nizar Y. Saad, Setty M. Magaña, Willa A. Hsueh, Rachel E. Kopec, Blaise R. Kimmel, Andre F. Palmer, Eduardo Reátegui   +23 more
wiley   +1 more source

Pathologic landscape of HER2-low in gastroesophageal adenocarcinoma: real-world data [PDF]

, 2022
openBackground. Human epidermal growth factor receptor 2 (HER2) is the first molecular biomarker which has been exploited for advanced gastroesophageal cancers’ targeted therapy.
BASTASIN, MARTINA
core